PRMT3 and neoplasm: Consistent with our findings from the Prmt3-KO cells, SGC707 delayed tumor progression in both immune-deficient and immune-competent mice, and its effects were more profound in immune-competent mice than in immune-deficient mice (Fig. 3H–K and Supplementary Fig. 5E–G).